Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death∗
Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephanie Chamberlain, Johnson Ung, Stephen J. F. Chong, Matthew S. Davids · 2026
Read Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death∗ by Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephanie Chamberlain, Johnson Ung, Stephen J. F. Chong, Matthew S. Davids (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13312011.txt.
Description
Fen Zhu and co-authors show that blocking an enzyme primes lymphoma cells to die through two routes at once, in a 2026 study. The enzyme, PRMT5, is overproduced in aggressive B-cell cancers. A drug against it engages its target well but works weakly alone in patients. So the team hunted for partners using a profiling test. That test measures how close cells sit to programmed death.
The blocker pushed cells nearer to death and, in two lymphoma types, made them depend more on a survival protein, BCL-2. Pairing the blocker with a BCL-2 drug then killed those cells in synergy. Separately, the blocker raised two death receptors on the cell surface, sensitizing even the less BCL-2-dependent lines to an outside death signal. The authors propose these pairings as rational combinations to test in B-cell lymphoma treatment.
Catalog record
| CREATOR | Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephanie Chamberlain, Johnson Ung, Stephen J. F. Chong, Matthew S. Davids |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |